Skip to main content
PMC home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 1997 Apr;47(417):235–240.

Benign prostatic hyperplasia.

R J Simpson 1
PMCID: PMC1312951  PMID: 9196969

Abstract

The clinical syndrome of benign prostatic hyperplasia reflects a complex interplay between benign prostatic enlargement, which will affect almost all men by the age of 80, and the resulting outlet obstruction and lower urinary tract symptoms. The disease is now known to adversely affect the quality of life of around one man in three over the age of 50. New medical treatments and new surgical interventions are challenging the previous standard treatment of transurethral resection of prostate, which continues to have a morbidity of 17% and some mortality. Primary care will be increasingly involved in shared care with particular emphasis on monitoring of patients on watchful waiting medical therapy- and following operative intervention.

Full Text

The Full Text of this article is available as a PDF (60.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams P. H., Griffiths D. J. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol. 1979 Apr;51(2):129–134. doi: 10.1111/j.1464-410x.1979.tb02846.x. [DOI] [PubMed] [Google Scholar]
  2. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994 Apr 9;308(6934):929–930. doi: 10.1136/bmj.308.6934.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andersen J. T., Nordling J., Walter S. Prostatism. I. The correlation between symptoms, cystometric and urodynamic findings. Scand J Urol Nephrol. 1979;13(3):229–236. doi: 10.3109/00365597909179530. [DOI] [PubMed] [Google Scholar]
  4. Araki H., Watanabe H., Mishina T., Nakao M. High-risk group for benign prostatic hypertrophy. Prostate. 1983;4(3):253–264. doi: 10.1002/pros.2990040305. [DOI] [PubMed] [Google Scholar]
  5. Ball A. J., Feneley R. C., Abrams P. H. The natural history of untreated "prostatism". Br J Urol. 1981 Dec;53(6):613–616. doi: 10.1111/j.1464-410x.1981.tb03273.x. [DOI] [PubMed] [Google Scholar]
  6. Barry M. J., Fowler F. J., Jr, Mulley A. G., Jr, Henderson J. V., Jr, Wennberg J. E. Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hyperplasia. Med Care. 1995 Aug;33(8):771–782. doi: 10.1097/00005650-199508000-00003. [DOI] [PubMed] [Google Scholar]
  7. Barry M. J., Fowler F. J., Jr, O'Leary M. P., Bruskewitz R. C., Holtgrewe H. L., Mebust W. K., Cockett A. T. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549–1564. doi: 10.1016/s0022-5347(17)36966-5. [DOI] [PubMed] [Google Scholar]
  8. Barry M. J., Girman C. J., O'Leary M. P., Walker-Corkery E. S., Binkowitz B. S., Cockett A. T., Guess H. A. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J Urol. 1995 Jan;153(1):99–103. doi: 10.1097/00005392-199501000-00036. [DOI] [PubMed] [Google Scholar]
  9. Barry M. J., Mulley A. G., Jr, Fowler F. J., Wennberg J. W. Watchful waiting vs immediate transurethral resection for symptomatic prostatism. The importance of patients' preferences. JAMA. 1988 May 27;259(20):3010–3017. [PubMed] [Google Scholar]
  10. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–479. doi: 10.1016/s0022-5347(17)49698-4. [DOI] [PubMed] [Google Scholar]
  11. Birkhoff J. D., Wiederhorn A. R., Hamilton M. L., Zinsser H. H. Natural history of benign prostatic hypertrophy and acute urinary retention. Urology. 1976 Jan;7(1):48–52. doi: 10.1016/0090-4295(76)90560-4. [DOI] [PubMed] [Google Scholar]
  12. Blute M. L., Tomera K. M., Hellerstein D. K., McKiel C. F., Jr, Lynch J. H., Regan J. B., Sankey N. E. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia: results of the United States Prostatron Cooperative Study. J Urol. 1993 Nov;150(5 Pt 2):1591–1596. doi: 10.1016/s0022-5347(17)35852-4. [DOI] [PubMed] [Google Scholar]
  13. Bourke J. B., Griffin J. P. Diabetes mellitus in patients with benign prostatic hyperplasia. Br Med J. 1968 Nov 23;4(5629):492–493. doi: 10.1136/bmj.4.5629.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Boyarsky S., Jones G., Paulson D. F., Prout G. R., Jr A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1976;68:29–32. [PubMed] [Google Scholar]
  15. Boyle P. New insights into the epidemiology and natural history of benign prostatic hyperplasia. Prog Clin Biol Res. 1994;386:3–18. [PubMed] [Google Scholar]
  16. Bruskewitz R. C., Iversen P., Madsen P. O. Value of postvoid residual urine determination in evaluation of prostatism. Urology. 1982 Dec;20(6):602–604. doi: 10.1016/0090-4295(82)90308-9. [DOI] [PubMed] [Google Scholar]
  17. Buck A. C., Cox R., Rees R. W., Ebeling L., John A. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study. Br J Urol. 1990 Oct;66(4):398–404. doi: 10.1111/j.1464-410x.1990.tb14962.x. [DOI] [PubMed] [Google Scholar]
  18. Chancellor M. B., Rivas D. A., Keeley F. X., Lotfi M. A., Gomella L. G. Similarity of the American Urological Association Symptom Index among men with benign prostate hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br J Urol. 1994 Aug;74(2):200–203. doi: 10.1111/j.1464-410x.1994.tb16586.x. [DOI] [PubMed] [Google Scholar]
  19. Chisholm G. D. Benign prostatic hyperplasia: the best treatment. BMJ. 1989 Jul 22;299(6693):215–216. doi: 10.1136/bmj.299.6693.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chisholm G. D., Carne S. J., Fitzpatrick J. M., George N. J., Gingell J. C., Keen J. W., Kirby R. S., Kirk D., O'Donoghue E. P., Peeling W. B. Prostate disease: management options for the primary healthcare team. Report of a working party of the British Prostate Group. Postgrad Med J. 1995 Mar;71(833):136–142. doi: 10.1136/pgmj.71.833.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Christensen M. M., Bruskewitz R. C. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am. 1990 Aug;17(3):509–516. [PubMed] [Google Scholar]
  22. Chute C. G., Panser L. A., Girman C. J., Oesterling J. E., Guess H. A., Jacobsen S. J., Lieber M. M. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993 Jul;150(1):85–89. doi: 10.1016/s0022-5347(17)35405-8. [DOI] [PubMed] [Google Scholar]
  23. Chyou P. H., Nomura A. M., Stemmermann G. N., Hankin J. H. A prospective study of alcohol, diet, and other lifestyle factors in relation to obstructive uropathy. Prostate. 1993;22(3):253–264. doi: 10.1002/pros.2990220308. [DOI] [PubMed] [Google Scholar]
  24. Craigen A. A., Hickling J. B., Saunders C. R., Carpenter R. G. Natural history of prostatic obstruction. A prospective survey. J R Coll Gen Pract. 1969 Oct;18(87):226–232. [PMC free article] [PubMed] [Google Scholar]
  25. Cunningham-Burley S., Allbutt H., Garraway W. M., Lee A. J., Russell E. B. Perceptions of urinary symptoms and health-care-seeking behaviour amongst men aged 40-79 years. Br J Gen Pract. 1996 Jun;46(407):349–352. [PMC free article] [PubMed] [Google Scholar]
  26. Doll H. A., Black N. A., McPherson K., Flood A. B., Williams G. B., Smith J. C. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992 Jun;147(6):1566–1573. doi: 10.1016/s0022-5347(17)37628-0. [DOI] [PubMed] [Google Scholar]
  27. Donatucci C. F., Berger N., Kreder K. J., Donohue R. E., Raife M. J., Crawford E. D. Randomized clinical trial comparing balloon dilatation to transurethral resection of prostate for benign prostatic hyperplasia. Urology. 1993 Jul;42(1):42–49. doi: 10.1016/0090-4295(93)90335-8. [DOI] [PubMed] [Google Scholar]
  28. Drach G. W., Layton T. N., Binard W. J. Male peak urinary flow rate: relationships to volume voided and age. J Urol. 1979 Aug;122(2):210–214. doi: 10.1016/s0022-5347(17)56333-8. [DOI] [PubMed] [Google Scholar]
  29. Dutartre D., Susset J. G. Reproductibilité des courbes de débitmétrie urinaire. J Urol Nephrol (Paris) 1974 Dec;80(12 Pt 2):484–494. [PubMed] [Google Scholar]
  30. Emberton M., Neal D. E., Black N., Harrison M., Fordham M., McBrien M. P., Williams R. E., McPherson K., Devlin H. B. The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol. 1995 Mar;75(3):301–316. doi: 10.1111/j.1464-410x.1995.tb07341.x. [DOI] [PubMed] [Google Scholar]
  31. Feest T. G., Round A., Hamad S. Incidence of severe acute renal failure in adults: results of a community based study. BMJ. 1993 Feb 20;306(6876):481–483. doi: 10.1136/bmj.306.6876.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Fowler F. J., Jr, Wennberg J. E., Timothy R. P., Barry M. J., Mulley A. G., Jr, Hanley D. Symptom status and quality of life following prostatectomy. JAMA. 1988 May 27;259(20):3018–3022. [PubMed] [Google Scholar]
  33. Fowler F. J. Patient reports of symptoms and quality of life following prostate surgery. Eur Urol. 1991;20 (Suppl 1):44–49. doi: 10.1159/000471746. [DOI] [PubMed] [Google Scholar]
  34. Fuglsig S., Aagaard J., Jønler M., Olesen S., Nørgaard J. P. Survival after transurethral resection of the prostate: a 10-year followup. J Urol. 1994 Mar;151(3):637–639. doi: 10.1016/s0022-5347(17)35035-8. [DOI] [PubMed] [Google Scholar]
  35. Garraway W. M., Armstrong C., Auld S., King D., Simpson R. J. Follow-up of a cohort of men with untreated benign prostatic hyperplasia. Eur Urol. 1993;24(3):313–318. doi: 10.1159/000474320. [DOI] [PubMed] [Google Scholar]
  36. Garraway W. M., Collins G. N., Lee R. J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991 Aug 24;338(8765):469–471. doi: 10.1016/0140-6736(91)90543-x. [DOI] [PubMed] [Google Scholar]
  37. Garraway W. M., Russell E. B., Lee R. J., Collins G. N., McKelvie G. B., Hehir M., Rogers A. C., Simpson R. J. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract. 1993 Aug;43(373):318–321. [PMC free article] [PubMed] [Google Scholar]
  38. Glynn R. J., Campion E. W., Bouchard G. R., Silbert J. E. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985 Jan;121(1):78–90. [PubMed] [Google Scholar]
  39. Grosse H. Frequenz, Lokalisation und Begleiterkrankungen der Harnsteine. Analyse von 1671 Urolithiasis-Obduktionen. Z Urol Nephrol. 1990 Sep;83(9):469–474. [PubMed] [Google Scholar]
  40. Guess H. A., Arrighi H. M., Metter E. J., Fozard J. L. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17(3):241–246. doi: 10.1002/pros.2990170308. [DOI] [PubMed] [Google Scholar]
  41. Guess H. A., Heyse J. F., Gormley G. J. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22(1):31–37. doi: 10.1002/pros.2990220105. [DOI] [PubMed] [Google Scholar]
  42. HOLTGREWE H. L., VALK W. L. Factors influencing the mortality and morbidity of transurethral prostatectomy: a study of 2,015 cases. J Urol. 1962 Mar;87:450–459. doi: 10.1016/S0022-5347(17)64980-2. [DOI] [PubMed] [Google Scholar]
  43. Hargreave T. B., Stephenson T. P. Potency and prostatectomy. Br J Urol. 1977;49(7):683–688. doi: 10.1111/j.1464-410x.1977.tb04553.x. [DOI] [PubMed] [Google Scholar]
  44. Haylen B. T., Ashby D., Sutherst J. R., Frazer M. I., West C. R. Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. Br J Urol. 1989 Jul;64(1):30–38. doi: 10.1111/j.1464-410x.1989.tb05518.x. [DOI] [PubMed] [Google Scholar]
  45. Hedlund H., Andersson K. E., Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983 Aug;130(2):275–278. doi: 10.1016/s0022-5347(17)51106-4. [DOI] [PubMed] [Google Scholar]
  46. Imperato-McGinley J., Guerrero L., Gautier T., Peterson R. E. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974 Dec 27;186(4170):1213–1215. doi: 10.1126/science.186.4170.1213. [DOI] [PubMed] [Google Scholar]
  47. Jardin A., Bensadoun H., Delauche-Cavallier M. C., Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991 Jun 15;337(8755):1457–1461. doi: 10.1016/0140-6736(91)93140-5. [DOI] [PubMed] [Google Scholar]
  48. Jensen K. M., Jørgensen J. B., Mogensen P., Bille-Brahe N. E. Some clinical aspects of uroflowmetry in elderly males. A population survey. Scand J Urol Nephrol. 1986;20(2):93–99. doi: 10.3109/00365598609040555. [DOI] [PubMed] [Google Scholar]
  49. Jensen K. M., Jørgensen J. B., Mogensen P. Relationship between urinary flow curve patterns and symptomatology in elderly males. Scand J Urol Nephrol Suppl. 1987;104:69–71. [PubMed] [Google Scholar]
  50. Jensen K. M., Jørgensen J. B., Mogensen P. Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand J Urol Nephrol. 1988;22(2):109–117. doi: 10.1080/00365599.1988.11690395. [DOI] [PubMed] [Google Scholar]
  51. Jensen K. M., Jørgensen J. B., Mogensen P. Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand J Urol Nephrol. 1988;22(2):109–117. doi: 10.1080/00365599.1988.11690395. [DOI] [PubMed] [Google Scholar]
  52. Jensen K. M., Jørgensen J. B., Mogensen P. Urodynamics in prostatism. I. Prognostic value of uroflowmetry. Scand J Urol Nephrol. 1988;22(2):109–117. doi: 10.1080/00365599.1988.11690395. [DOI] [PubMed] [Google Scholar]
  53. Jørgensen J. B., Jensen K. M., Bille-Brahe N. E., Morgensen P. Uroflowmetry in asymptomatic elderly males. Br J Urol. 1986 Aug;58(4):390–395. doi: 10.1111/j.1464-410x.1986.tb09092.x. [DOI] [PubMed] [Google Scholar]
  54. Kaufman J., Dhakal M., Patel B., Hamburger R. Community-acquired acute renal failure. Am J Kidney Dis. 1991 Feb;17(2):191–198. doi: 10.1016/s0272-6386(12)81128-0. [DOI] [PubMed] [Google Scholar]
  55. Lepor H., Auerbach S., Puras-Baez A., Narayan P., Soloway M., Lowe F., Moon T., Leifer G., Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992 Nov;148(5):1467–1474. doi: 10.1016/s0022-5347(17)36941-0. [DOI] [PubMed] [Google Scholar]
  56. Lepor H., Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology. 1993 Jul;42(1):36–41. doi: 10.1016/0090-4295(93)90332-5. [DOI] [PubMed] [Google Scholar]
  57. Libman E., Fichten C. S., Creti L., Weinstein N., Amsel R., Brender W. Transurethral prostatectomy: differential effects of age category and presurgery sexual functioning on postprostatectomy sexual adjustment. J Behav Med. 1989 Oct;12(5):469–485. doi: 10.1007/BF00844879. [DOI] [PubMed] [Google Scholar]
  58. Lloyd S. N., McMahon A., Muller W., Buckley J. F., Deane R. F., Kirk D., Kyle K. F. Is indoramin an effective alternative to prostatectomy? Br J Urol. 1992 Oct;70(4):408–411. doi: 10.1111/j.1464-410x.1992.tb15798.x. [DOI] [PubMed] [Google Scholar]
  59. McNeal J. E. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978 Jan;15(4):340–345. [PubMed] [Google Scholar]
  60. McNeal J. E. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968 Mar;49(3):347–357. doi: 10.1093/ajcp/49.3.347. [DOI] [PubMed] [Google Scholar]
  61. Mebust W. K., Holtgrewe H. L., Cockett A. T., Peters P. C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989 Feb;141(2):243–247. doi: 10.1016/s0022-5347(17)40731-2. [DOI] [PubMed] [Google Scholar]
  62. Mebust W. K. Surgical management of benign prostatic obstruction. Urology. 1988 Dec;32(6 Suppl):12–15. [PubMed] [Google Scholar]
  63. Melchior J., Valk W. L., Foret J. D., Mebust W. K. Transurethral prostatectomy: computerized analysis of 2,223 consecutive cases. J Urol. 1974 Nov;112(5):634–642. doi: 10.1016/s0022-5347(17)59817-1. [DOI] [PubMed] [Google Scholar]
  64. Morrison A. S. Prostatic hypertrophy in greater Boston. J Chronic Dis. 1978;31(5):357–362. doi: 10.1016/0021-9681(78)90052-8. [DOI] [PubMed] [Google Scholar]
  65. Neal D. E., Ramsden P. D., Sharples L., Smith A., Powell P. H., Styles R. A., Webb R. J. Outcome of elective prostatectomy. BMJ. 1989 Sep 23;299(6702):762–767. doi: 10.1136/bmj.299.6702.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Nielsen H. O. Transurethral prostatotomy versus transurethral prostatectomy in benign prostatic hypertrophy. A prospective randomised study. Br J Urol. 1988 May;61(5):435–438. doi: 10.1111/j.1464-410x.1988.tb06592.x. [DOI] [PubMed] [Google Scholar]
  67. Nomura A. M., Kolonel L. N. Prostate cancer: a current perspective. Epidemiol Rev. 1991;13:200–227. doi: 10.1093/oxfordjournals.epirev.a036069. [DOI] [PubMed] [Google Scholar]
  69. Partin A. W., Page W. F., Lee B. R., Sanda M. G., Miller R. N., Walsh P. C. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology. 1994 Nov;44(5):646–650. doi: 10.1016/s0090-4295(94)80197-5. [DOI] [PubMed] [Google Scholar]
  70. Powell P. H., Smith P. J., Feneley R. C. The identification of patients at risk from acute retention. Br J Urol. 1980 Dec;52(6):520–522. doi: 10.1111/j.1464-410x.1980.tb03104.x. [DOI] [PubMed] [Google Scholar]
  71. Poznanski E., Poznanski A. K. Psychogenic influences on voiding: observations from voiding cystourethrography. Psychosomatics. 1969 Nov;10(6):339–342. doi: 10.1016/S0033-3182(69)71701-7. [DOI] [PubMed] [Google Scholar]
  72. Prescott R. J., Garraway W. M. Regression to the mean occurs in measuring peak urinary flow. Br J Urol. 1995 Nov;76(5):611–613. doi: 10.1111/j.1464-410x.1995.tb07787.x. [DOI] [PubMed] [Google Scholar]
  73. RICHARDSON I. M. PROSTATIC HYPERPLASIA AND SOCIAL CLASS. Br J Prev Soc Med. 1964 Jul;18:157–162. doi: 10.1136/jech.18.3.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Roberts R. O., Jacobsen S. J., Rhodes T., Guess H. A., Girman C. J., Panser L. A., Chute C. G., Oesterling J. E., Lieber M. M. Cigarette smoking and prostatism: a biphasic association? Urology. 1994 Jun;43(6):797–801. doi: 10.1016/0090-4295(94)90138-4. [DOI] [PubMed] [Google Scholar]
  75. Roos N. P., Wennberg J. E., Malenka D. J., Fisher E. S., McPherson K., Andersen T. F., Cohen M. M., Ramsey E. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989 Apr 27;320(17):1120–1124. doi: 10.1056/NEJM198904273201705. [DOI] [PubMed] [Google Scholar]
  76. Rowan D., McKenzie A. L., McNee S. G., Glen E. S. A technical and clinical evaluation of the Disa uroflowmeter. Br J Urol. 1977 Aug;49(4):285–291. doi: 10.1111/j.1464-410x.1977.tb04138.x. [DOI] [PubMed] [Google Scholar]
  77. Ryall R. L., Marshall V. R. Measurement of urinary flow rate. Urology. 1983 Nov;22(5):556–564. doi: 10.1016/0090-4295(83)90245-5. [DOI] [PubMed] [Google Scholar]
  78. STUMPF H. H., WILENS S. L. Inhibitory effects of portal cirrhosis of liver on prostatic enlargement. AMA Arch Intern Med. 1953 Mar;91(3):304–309. doi: 10.1001/archinte.1953.00240150023003. [DOI] [PubMed] [Google Scholar]
  79. Sacks S. H., Aparicio S. A., Bevan A., Oliver D. O., Will E. J., Davison A. M. Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ. 1989 Jan 21;298(6667):156–159. doi: 10.1136/bmj.298.6667.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Sanda M. G., Beaty T. H., Stutzman R. E., Childs B., Walsh P. C. Genetic susceptibility of benign prostatic hyperplasia. J Urol. 1994 Jul;152(1):115–119. doi: 10.1016/s0022-5347(17)32831-8. [DOI] [PubMed] [Google Scholar]
  81. Simpson R. J., Fisher W., Lee A. J., Russell E. B., Garraway M. Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol. 1996 Feb;77(2):186–191. doi: 10.1046/j.1464-410x.1996.08593.x. [DOI] [PubMed] [Google Scholar]
  82. Simpson R. J., Lee R. J., Garraway W. M., King D., McIntosh I. Consultation patterns in a community survey of men with benign prostatic hyperplasia. Br J Gen Pract. 1994 Nov;44(388):499–502. [PMC free article] [PubMed] [Google Scholar]
  83. Sirls L. T., Ganabathi K., Zimmern P. E., Roskamp D. A., Wolde-Tsadik G., Leach G. E. Transurethral incision of the prostate: an objective and subjective evaluation of long-term efficacy. J Urol. 1993 Nov;150(5 Pt 2):1615–1621. doi: 10.1016/s0022-5347(17)35858-5. [DOI] [PubMed] [Google Scholar]
  84. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol. 1992 May;147(5):1298–1302. doi: 10.1016/s0022-5347(17)37547-x. [DOI] [PubMed] [Google Scholar]
  85. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994 Mar;43(3):284–294. doi: 10.1016/0090-4295(94)90068-x. [DOI] [PubMed] [Google Scholar]
  86. Thorpe A. C., Cleary R., Coles J., Reynolds J., Vernon S., Neal D. E. Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol. 1994 Oct;74(4):479–484. doi: 10.1111/j.1464-410x.1994.tb00427.x. [DOI] [PubMed] [Google Scholar]
  87. Thorpe A. C., Cleary R., Coles J., Vernon S., Reynolds J., Neal D. E. Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. Br J Urol. 1994 Nov;74(5):559–565. doi: 10.1111/j.1464-410x.1994.tb09184.x. [DOI] [PubMed] [Google Scholar]
  88. Vaughan E. D., Jr, Perlmutter A. P. An evolving picture: albeit hazy. J Urol. 1993 Nov;150(5 Pt 2):1622–1623. doi: 10.1016/s0022-5347(17)35859-7. [DOI] [PubMed] [Google Scholar]
  89. Wasserman N. F., Reddy P. K., Zhang G., Berg P. A. Experimental treatment of benign prostatic hyperplasia with transurethral balloon dilation of the prostate: preliminary study in 73 humans. Radiology. 1990 Nov;177(2):485–494. doi: 10.1148/radiology.177.2.1699247. [DOI] [PubMed] [Google Scholar]
  90. Wasson J. H., Reda D. J., Bruskewitz R. C., Elinson J., Keller A. M., Henderson W. G. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995 Jan 12;332(2):75–79. doi: 10.1056/NEJM199501123320202. [DOI] [PubMed] [Google Scholar]
  91. Watanabe H. Natural history of benign prostatic hypertrophy. Ultrasound Med Biol. 1986 Jul;12(7):567–571. doi: 10.1016/0301-5629(86)90100-6. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES